233 related articles for article (PubMed ID: 35732347)
21. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
[TBL] [Abstract][Full Text] [Related]
22. Nasal administration of recombinant
Battistoni A; Lantier L; di Tommaso A; Ducournau C; Lajoie L; Samimi M; Coënon L; Rivière C; Epardaud M; Hertereau L; Poupée-Beaugé A; Rieu J; Mévélec MN; Lee GS; Moiré N; Germon S; Dimier-Poisson I
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37192784
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
24. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
25. Immunostimulant Hydrogel-Guided Tumor Microenvironment Reprogramming to Efficiently Potentiate Macrophage-Mediated Cellular Phagocytosis for Systemic Cancer Immunotherapy.
Liang JL; Jin XK; Luo GF; Zhang SM; Huang QX; Lin YT; Deng XC; Wang JW; Chen WH; Zhang XZ
ACS Nano; 2023 Sep; 17(17):17217-17232. PubMed ID: 37584451
[TBL] [Abstract][Full Text] [Related]
26. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
27. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.
Umansky V; Sevko A
Cancer Immunol Immunother; 2012 Feb; 61(2):275-282. PubMed ID: 22120757
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
30. Enhanced antigen-presenting activity and tumour necrosis factor-alpha-independent activation of dendritic cells following treatment with Mycobacterium bovis bacillus Calmette-Guérin.
Kim KD; Lee HG; Kim JK; Park SN; Choe IS; Choe YK; Kim SJ; Lee E; Lim JS
Immunology; 1999 Aug; 97(4):626-33. PubMed ID: 10457216
[TBL] [Abstract][Full Text] [Related]
31. Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma.
Bararia D; Hildebrand JA; Stolz S; Haebe S; Alig S; Trevisani CP; Osorio-Barrios F; Bartoschek MD; Mentz M; Pastore A; Gaitzsch E; Heide M; Jurinovic V; Rautter K; Gunawardana J; Sabdia MB; Szczepanowski M; Richter J; Klapper W; Louissaint A; Ludwig C; Bultmann S; Leonhardt H; Eustermann S; Hopfner KP; Hiddemann W; von Bergwelt-Baildon M; Steidl C; Kridel R; Tobin JWD; Gandhi MK; Weinstock DM; Schmidt-Supprian M; Sárosi MB; Rudelius M; Passerini V; Mautner J; Weigert O
Cell Rep; 2020 May; 31(5):107522. PubMed ID: 32330423
[TBL] [Abstract][Full Text] [Related]
32. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
33. Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1.
Liu H; Innamarato PP; Kodumudi K; Weber A; Nemoto S; Robinson JL; Crago G; McCardle T; Royster E; Sarnaik AA; Pilon-Thomas S
Oncotarget; 2016 Jun; 7(25):37893-37905. PubMed ID: 27177220
[TBL] [Abstract][Full Text] [Related]
34. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
[TBL] [Abstract][Full Text] [Related]
35. Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor.
You D; Hillerman S; Locke G; Chaudhry C; Stromko C; Murtaza A; Fan Y; Koenitzer J; Chen Y; Briceno S; Bhadra R; Duperret E; Gullo-Brown J; Gao C; Zhao D; Feder J; Curtin J; Degnan AP; Kumi G; Wittman M; Johnson BM; Parrish KE; Gokulrangan G; Morrison J; Quigley M; Hunt JT; Salter-Cid L; Lees E; Sanjuan MA; Liu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408094
[TBL] [Abstract][Full Text] [Related]
36. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
Dai X; Meng J; Deng S; Zhang L; Wan C; Lu L; Huang J; Hu Y; Zhang Z; Li Y; Lovell JF; Wu G; Yang K; Jin H
Theranostics; 2020; 10(7):3049-3063. PubMed ID: 32194854
[TBL] [Abstract][Full Text] [Related]
37. Rapid loss of early antigen-presenting activity of lymph node dendritic cells against Ag85A protein following Mycobacterium bovis BCG infection.
Xu Z; Xia A; Li X; Zhu Z; Shen Y; Jin S; Lan T; Xie Y; Wu H; Meng C; Sun L; Yin Y; Chen X; Jiao X
BMC Immunol; 2018 Jun; 19(1):19. PubMed ID: 29940854
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant
Oba T; Kajihara R; Yokoi T; Repasky EA; Ito F
Cancer Res; 2021 Dec; 81(24):6183-6195. PubMed ID: 34666993
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of pulmonary metastases of B16 melanoma with irradiated tumor cells and BCG.
Tai J; Guclu A; Ghose T; Norvell S
Cancer Immunol Immunother; 1983; 15(1):47-53. PubMed ID: 6553507
[TBL] [Abstract][Full Text] [Related]
40. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.
Mastrangelo MJ; Bellet RE; Berkelhammer J; Clark WH
Cancer; 1975 Oct; 36(4):1305-8. PubMed ID: 1175129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
